Optimizing treatment outcomeswith regorafenib: Personalized dosing and other strategies to support patient care

Axel F Grothey, Suzanne George, Eric van Cutsem, Jean Yves Blay, Alberto Sobrero, George D. Demetri

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients with metastatic CRC progressing after all available standard therapies, and significantly prolonged progression-free survival in patients with advanced GIST in whom at least imatinib and sunitinib had failed. Thus, this agent holds promise as a new standard of care for CRC and GIST patients after disease progression following all other approved therapies.The clinical trials reported to date show that this new treatment has a consistent adverse event profile that is quite different from that of traditional cytotoxic chemotherapies. The most common adverse events of regorafenib include dermatologic and mucosal toxicities (especially hand-foot skin reaction, rash, and oral mucositis), constitutional symptoms (e.g., fatigue, nausea, and weight loss), vascular effects (especially hypertension), and gastrointestinal symptoms (e.g., diarrhea). To help health care professionals anticipate and manage the adverse events associated with regorafenib, we describe our experiences in clinical trials and show that such toxicities can be effectively managed with close observation of patients from initiation of dosing, along with prompt appropriate interventions, including dose modifications, if necessary.

Original languageEnglish (US)
Pages (from-to)669-680
Number of pages12
JournalOncologist
Volume19
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Gastrointestinal Stromal Tumors
Patient Care
Colorectal Neoplasms
Clinical Trials
Stomatitis
Therapeutics
Standard of Care
Exanthema
Nausea
Disease-Free Survival
Fatigue
Blood Vessels
Disease Progression
Foot
Weight Loss
Diarrhea
Neoplasms
Phosphotransferases
Hand
Placebos

Keywords

  • Adverse events
  • Dose optimization
  • Hand-foot skin reaction
  • Multikinase inhibitor
  • Regorafenib
  • Supportive management

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Grothey, A. F., George, S., van Cutsem, E., Blay, J. Y., Sobrero, A., & Demetri, G. D. (2014). Optimizing treatment outcomeswith regorafenib: Personalized dosing and other strategies to support patient care. Oncologist, 19(6), 669-680. https://doi.org/10.1634/theoncologist.2013-0059

Optimizing treatment outcomeswith regorafenib : Personalized dosing and other strategies to support patient care. / Grothey, Axel F; George, Suzanne; van Cutsem, Eric; Blay, Jean Yves; Sobrero, Alberto; Demetri, George D.

In: Oncologist, Vol. 19, No. 6, 2014, p. 669-680.

Research output: Contribution to journalArticle

Grothey, AF, George, S, van Cutsem, E, Blay, JY, Sobrero, A & Demetri, GD 2014, 'Optimizing treatment outcomeswith regorafenib: Personalized dosing and other strategies to support patient care', Oncologist, vol. 19, no. 6, pp. 669-680. https://doi.org/10.1634/theoncologist.2013-0059
Grothey, Axel F ; George, Suzanne ; van Cutsem, Eric ; Blay, Jean Yves ; Sobrero, Alberto ; Demetri, George D. / Optimizing treatment outcomeswith regorafenib : Personalized dosing and other strategies to support patient care. In: Oncologist. 2014 ; Vol. 19, No. 6. pp. 669-680.
@article{56161798ab474574bfac4d81432237f1,
title = "Optimizing treatment outcomeswith regorafenib: Personalized dosing and other strategies to support patient care",
abstract = "Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients with metastatic CRC progressing after all available standard therapies, and significantly prolonged progression-free survival in patients with advanced GIST in whom at least imatinib and sunitinib had failed. Thus, this agent holds promise as a new standard of care for CRC and GIST patients after disease progression following all other approved therapies.The clinical trials reported to date show that this new treatment has a consistent adverse event profile that is quite different from that of traditional cytotoxic chemotherapies. The most common adverse events of regorafenib include dermatologic and mucosal toxicities (especially hand-foot skin reaction, rash, and oral mucositis), constitutional symptoms (e.g., fatigue, nausea, and weight loss), vascular effects (especially hypertension), and gastrointestinal symptoms (e.g., diarrhea). To help health care professionals anticipate and manage the adverse events associated with regorafenib, we describe our experiences in clinical trials and show that such toxicities can be effectively managed with close observation of patients from initiation of dosing, along with prompt appropriate interventions, including dose modifications, if necessary.",
keywords = "Adverse events, Dose optimization, Hand-foot skin reaction, Multikinase inhibitor, Regorafenib, Supportive management",
author = "Grothey, {Axel F} and Suzanne George and {van Cutsem}, Eric and Blay, {Jean Yves} and Alberto Sobrero and Demetri, {George D.}",
year = "2014",
doi = "10.1634/theoncologist.2013-0059",
language = "English (US)",
volume = "19",
pages = "669--680",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - Optimizing treatment outcomeswith regorafenib

T2 - Personalized dosing and other strategies to support patient care

AU - Grothey, Axel F

AU - George, Suzanne

AU - van Cutsem, Eric

AU - Blay, Jean Yves

AU - Sobrero, Alberto

AU - Demetri, George D.

PY - 2014

Y1 - 2014

N2 - Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients with metastatic CRC progressing after all available standard therapies, and significantly prolonged progression-free survival in patients with advanced GIST in whom at least imatinib and sunitinib had failed. Thus, this agent holds promise as a new standard of care for CRC and GIST patients after disease progression following all other approved therapies.The clinical trials reported to date show that this new treatment has a consistent adverse event profile that is quite different from that of traditional cytotoxic chemotherapies. The most common adverse events of regorafenib include dermatologic and mucosal toxicities (especially hand-foot skin reaction, rash, and oral mucositis), constitutional symptoms (e.g., fatigue, nausea, and weight loss), vascular effects (especially hypertension), and gastrointestinal symptoms (e.g., diarrhea). To help health care professionals anticipate and manage the adverse events associated with regorafenib, we describe our experiences in clinical trials and show that such toxicities can be effectively managed with close observation of patients from initiation of dosing, along with prompt appropriate interventions, including dose modifications, if necessary.

AB - Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients with metastatic CRC progressing after all available standard therapies, and significantly prolonged progression-free survival in patients with advanced GIST in whom at least imatinib and sunitinib had failed. Thus, this agent holds promise as a new standard of care for CRC and GIST patients after disease progression following all other approved therapies.The clinical trials reported to date show that this new treatment has a consistent adverse event profile that is quite different from that of traditional cytotoxic chemotherapies. The most common adverse events of regorafenib include dermatologic and mucosal toxicities (especially hand-foot skin reaction, rash, and oral mucositis), constitutional symptoms (e.g., fatigue, nausea, and weight loss), vascular effects (especially hypertension), and gastrointestinal symptoms (e.g., diarrhea). To help health care professionals anticipate and manage the adverse events associated with regorafenib, we describe our experiences in clinical trials and show that such toxicities can be effectively managed with close observation of patients from initiation of dosing, along with prompt appropriate interventions, including dose modifications, if necessary.

KW - Adverse events

KW - Dose optimization

KW - Hand-foot skin reaction

KW - Multikinase inhibitor

KW - Regorafenib

KW - Supportive management

UR - http://www.scopus.com/inward/record.url?scp=84901937880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901937880&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2013-0059

DO - 10.1634/theoncologist.2013-0059

M3 - Article

C2 - 24821824

AN - SCOPUS:84901937880

VL - 19

SP - 669

EP - 680

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 6

ER -